Home / Products / Dermatology Portfolio / Plan long-term management

Print page content Print
Increase text size Decrease text size
Text Size

Plan for long-term management

Partner with your clients Decide on a long-term management plan that includes the Zoetis Dermatology Portfolio

Setting expectations and preparing for pruritic flares can protect clients' trust in their veterinarian

  • Allergic dermatitis requires lifelong management—even when controlled, occasional flares can occur1
      • Pruritic flares are to be expected, especially for seasonally affected dogs
  • Prepare your clients for the possibility of flares by establishing an individualized plan
  • Reassure your clients that their dog's current anti-pruritic treatment is still working, but a diagnostic workup is needed to determine the cause of the flare
  • Apoquel® and Cytopoint® can be used to relieve itch while completing a diagnostic workup, while Convenia® treats bacterial skin infection. Simparica Trio® is a monthly chewable that starts killing fleas fast, within 4 hours, to help keep dogs protected

–

Guidance for Successful Flare Management

  • Prepare for the possibility of a flare by maintaining open, two-way communication with the pet owner
  • If you suspect a flare, schedule an exam for the dog to be seen
  • Do not stop using the dog's current anti-pruritic treatment during the flare
  • Complete the diagnostic workup so the underlying cause of the flare (eg, fleas, infection, dietary indiscretion) can be identified
  • Treat the flare with the appropriate therapy
  • If the flare is due to seasonal spikes in environmental allergens, add a second anti-pruritic treatment for the time needed to get the patient's pruritus under control again. APOQUEL and CYTOPOINT can be used together effectively and safely to treat seasonal flares

Navigating flare management with your clients

Dixon's story: Managing a flare of allergic disease2

  • 59 lb Labrador Retriever mix
  • Dixon presented with severe pruritus and was diagnosed with allergic dermatitis with secondary bacterial pyoderma
  • He was treated with Cytopoint to provide consistent itch relief that does not rely on his owner's ability to administer daily medication
  • A flea allergy flare caused Dixon to develop a secondary Staph pyoderma. Simparica® (sarolaner) Chewables was used to treat the fleas, while the pyoderma was treated with Convenia, another injectable ensuring 100% compliance3
  • Within 24 hours, Dixon's itch was significantly reduced. At the one-week recheck, his allergic dermatitis and bacterial skin infection had resolved
Exeland before CYTOPOINT for his atopic dermatitis
Before Treatment
Exeland after CYTOPOINT for his atopic dermatitis
After treatment

Relief for both pet and owner

"We have tried so many different things to alleviate his problems... by far, the CYTOPOINT and CONVENIA treatment has been the best response he's ever had."

- Megan, Dixon's owner
Next, Resources for your practice

APOQUEL INDICATIONS: Control of pruritus associated with allergic dermatitis and control of atopic dermatitis in dogs at least 12 months of age.

APOQUEL IMPORTANT SAFETY INFORMATION: Do not use APOQUEL® (oclacitinib tablet) in dogs less than 12 months of age or those with serious infections. APOQUEL may increase the chances of developing serious infections, and may cause existing parasitic skin infestations or pre-existing cancers to get worse. APOQUEL has not been tested in dogs receiving some medications including some commonly used to treat skin conditions such as corticosteroids and cyclosporine. Do not use in breeding, pregnant, or lactating dogs. Most common side effects are vomiting and diarrhea. APOQUEL has been used safely with many common medications including parasiticides, antibiotics and vaccines.

For more information, please see the full Prescribing Information.

CYTOPOINT INDICATIONS: CYTOPOINT has been shown to be effective for the treatment of dogs against allergic dermatitis and atopic dermatitis.

CONVENIA INDICATIONS: CONVENIA is indicated for the treatment of skin infections (secondary superficial pyoderma, abscesses, and wounds) in dogs caused by susceptible strains of Staphylococcus intermedius and Streptococcus canis (Group G).

CONVENIA IMPORTANT SAFETY INFORMATION: People with known hypersensitivity to penicillin or cephalosporins should avoid exposure to CONVENIA. Do not use in dogs or cats with a history of allergic reactions to penicillins or cephalosporins. Side effects for both dogs and cats include vomiting, diarrhea, decreased appetite/anorexia, and lethargy.

For more information, please see the full Prescribing Information.

SIMPARICA TRIO INDICATIONS: SIMPARICA TRIO is indicated for the prevention of heartworm disease caused by Dirofilaria immitis and for the treatment and control of roundworm (immature adult and adult Toxocara canis and adult Toxascaris leonina) and adult hookworm (Ancylostoma caninum and Uncinaria stenocephala) infections. SIMPARICA TRIO kills adult fleas (Ctenocephalides felis) and is indicated for the treatment and prevention of flea infestations, and the treatment and control of tick infestations with Amblyomma americanum (lone star tick), Amblyomma maculatum (Gulf Coast tick), Dermacentor variabilis (American dog tick), Ixodes scapularis (black-legged tick), and Rhipicephalus sanguineus (brown dog tick) for one month in dogs and puppies 8 weeks of age and older, and weighing 2.8 pounds or greater.

SIMPARICA TRIO IMPORTANT SAFETY INFORMATION: Use with caution in dogs with a history of seizures. SIMPARICA TRIO contains sarolaner, a member of the isoxazoline class, which has been associated with neurologic adverse reactions including tremors, ataxia, and seizures in dogs with or without a history of neurologic disorders. The safe use of SIMPARICA TRIO has not been evaluated in breeding, pregnant, or lactating dogs. The most frequently reported adverse reactions in clinical trials were vomiting and diarrhea.

For more information, please see the full Prescribing Information.

References: 1.  Olivry T, DeBoer D, Favrot C, et al. Treatment of canine atopic dermatitis: 2015 updated guidelines from the International Committee on Allergic Diseases of Animals (ICADA). BMC Vet Res. 2015;11:210. doi:10.1186/s12917-015-0514-6. 2. Data on file, Pet Owner Case Studies-Dixon, 2018, Zoetis Inc. 3. Six R, Cherni J, Chesebrough R, et al. Efficacy and safety of cefovecin in treating bacterial folliculitis, abscesses, or infected wounds in dogs. J Am Vet Med Assoc. 2008;233(3):433-439.

Testimonials represent individual experience only and the experiences and opinions herein may be unique to the patient and the speaker. Individual results may vary, considering the unique characteristics of the patient.

This site is intended for U.S. Animal Healthcare Professionals. The animal health information contained herein is provided for educational purposes only and is not intended to replace discussions with an animal healthcare professional. All decisions regarding the care of a veterinary patient must be made with an animal healthcare professional, considering the unique characteristics of the patient.

The product information provided in this site is intended only for residents of the United States. The products discussed herein may not have marketing authorization or may have different product labeling in different countries.

All trademarks are the property of Zoetis Services LLC or a related company or a licensor unless otherwise noted. NexGard is a trademark of the Boehringer Ingelheim group.
© 2021 Zoetis Services LLC. All rights reserved. ZPC-00064R4

×

CONTACT US

1-888-963-8471

Mon–Fri, 8:30am–8:00pm ET

zoetis logo United States flag United States

This site is intended for U.S. Animal Healthcare Professionals. The product information provided in this site is intended only for residents of the United States. The products discussed herein may not have marketing authorization or may have different product labeling in different countries. The animal health information contained herein is provided for educational purposes only and is not intended to replace discussions with an animal healthcare professional. All decisions regarding the care of a veterinary patient must be made with an animal healthcare professional, considering the unique characteristics of the patient.

All trademarks are the property of Zoetis Services LLC or a related company or a licensor unless otherwise noted. ©2022 Zoetis Services LLC. All rights reserved.